1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,340 | 4,420 | 09:02 | |
| 4,340 | 4,420 | 08:58 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.01. | Cytek Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.01. | Cytek Biosciences Preliminary Q4 Revenue Up 8% | 1 | RTTNews | ||
| 12.01. | Cytek Biosciences, Inc.: Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results | 63 | GlobeNewswire (Europe) | FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the... ► Artikel lesen | |
| 12.11.25 | Cytek Biosciences, Inc.: TIME Recognizes Cytek Biosciences as One of America's Growth Leaders of 2026 | 5 | GlobeNewswire (USA) | ||
| 06.11.25 | Cytek Biosciences, Inc.: Cytek Muse Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year | 4 | GlobeNewswire (USA) | ||
| 06.11.25 | Cytek reaffirms $196M-$205M 2025 revenue outlook as recurring businesses accelerate | 3 | Seeking Alpha | ||
| CYTEK BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 05.11.25 | Cytek Biosciences GAAP EPS of -$0.04 beats by $0.01, revenue of $52.3M beats by $1.16M | 5 | Seeking Alpha | ||
| 05.11.25 | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 29.10.25 | Cytek Biosciences, Inc.: Cytek Biosciences Deepens Commitment to Expanding Access to Flow Cytometry | 1.171 | GlobeNewswire (Europe) | FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc.... ► Artikel lesen | |
| 22.10.25 | Cytek Biosciences, Inc.: Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025 | 2 | GlobeNewswire (USA) | ||
| 16.10.25 | Cytek Biosciences Expands with New Facility in Amsterdam | 3 | Contract Pharma | ||
| 15.10.25 | Cytek Biosciences, Inc.: Cytek Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth | 1 | GlobeNewswire (USA) | ||
| 14.08.25 | Cytek Biosciences auf dem UBS Summit: Einblicke in innovative Proteomik-Technologien | 7 | Investing.com Deutsch | ||
| 07.08.25 | Cytek narrows 2025 revenue outlook to $196M-$205M amid recurring revenue growth and new product launches | 1 | Seeking Alpha | ||
| 06.08.25 | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08.25 | Cytek Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 18.03.25 | Cytek Biosciences, Inc.: Cytek Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek Muse Micro System | 445 | GlobeNewswire (Europe) | FREMONT, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Today, Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has added transformative capabilities to its iconic Cytek® Guava® Muse® cell analyzer... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,035 | -4,86 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| BIOFRONTERA | 2,400 | -4,38 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| CLINUVEL | 6,965 | -0,85 % | Clinuvel Pharmaceuticals Limited: CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies | EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery... ► Artikel lesen | |
| EDITAS MEDICINE | 1,750 | +0,69 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| ASEP MEDICAL | 0,131 | 0,00 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,540 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,360 | -4,84 % | Krebs-Impfstoff: Chance Teil 2: Phase-2-Start für den Brustkrebs-Impfstoff und starke CAR-T-Daten bei Eierstockkrebs.Wird 2026 der Wendepunkt? | ||
| CLEAN HARBORS | 219,50 | +0,23 % | What 11 Analyst Ratings Have To Say About Clean Harbors | ||
| LIR LIFE SCIENCES | 1,220 | -3,17 % | EQS-Media: LIR Life Sciences Corp.: Ein neues Pflaster gegen starkes Übergewicht - und warum das für viele Menschen wichtig werden dürfte | EQS-Media / 22.01.2026 / 14:56 CET/CEST
LIR Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9) arbeitet an einer neuen Art von Medikamenten gegen starkes Übergewicht. Dabei geht es... ► Artikel lesen | |
| MESOBLAST | 1,540 | -1,91 % | Mesoblast Limited: Real-World Commercial Experience with Ryoncil Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment | ||
| SPERO THERAPEUTICS | 2,010 | -1,95 % | Former Spero execs fined by SEC over antibiotic efficacy claims | ||
| CSTONE PHARMACEUTICALS | 0,570 | -4,20 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 976,000 SHARES, WITH ACCUMULATED ... | ||
| PROTALIX BIOTHERAPEUTICS | 1,750 | +1,16 % | EQS-News: Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement | EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
/ Key word(s): Agreement
Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement
17.12.2025... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 72,00 | -1,37 % | Palvella Therapeutics Inc.: Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved ... | Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in... ► Artikel lesen | |
| PURPLE BIOTECH | 0,662 | -0,30 % | Purple Biotech Ltd.: Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update | Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform... ► Artikel lesen |
Das Unternehmen CYTEK BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,400 Euro und damit +0,46 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTEK BIOSCIENCES INC finden Sie auf Wallstreet Online.